CSE:SILO

Silo Wellness Hires Two Veterans of Lifestyle Marketing and Cannabis Industry to Promote Marley Line of Functional & Psychedelic Mushroom Brand

Silo Wellness Inc. (CSE: SILO), a wellness company in the psychedelics and functional mushroom marketplaces, is pleased to announce the appointment of beer, wine and spirits brand marketing and communications expert, Stuart Kirby, as Vice President of Marketing & Communications as well as cannabis and hemp industries expert, Peter Holzworth, as Vice President of Business Development.

"I am delighted to welcome two very accomplished senior executives to key leadership positions with Silo Wellness," stated Douglas K. Gordon, Chief Executive Officer of Silo Wellness. "With a decorated career in the adult beverage industry marketing some of the most iconic brands in the space, I look forward to Stuart's creativity in delivering and amplifying the Marley licensing agreement we have just recently announced. I am equally excited to welcome Peter, who has tremendous experience in the cannabis and hemp industries, and to having him replicate that success within the psychedelic and functional mushroom category."

Kirby has more than twenty five years of experience with integrated strategic communications, brand public relations and consumer lifestyle marketing. He has overseen the marketing and communications functions for some of the most successful companies in their respective industries, such as the world's leading supplier of wine, E & J Gallo, two leading global PR firms, Edelman and Hill & Knowlton as well as the world's leading adult beverage supplier, DIAGEO.

Anchored to the belief that "with great opportunity comes an equal measure of responsibility," Kirby has led numerous corporate social responsibility efforts from environmental sustainability plans and global responsible consumption initiatives to cause-related marketing campaigns and humanitarian relief operations partnering with non-profit entities such as Amnesty International, Surfrider Foundation, Pan-American Development Foundation, USAID and Habitat for Humanity.

"Throughout my career, I have had the great privilege of being entrusted as steward to some of the most iconic, lifestyle brands in the world. Marketing and publicizing the legacy of Bob Marley – a man, musician and mystic that I have long admired – may be one of the most exciting professional opportunities I have ever been responsible for," commented Kirby. "I look forward to transforming this fast-moving industry with a brand that stands for ‘one love' and translating that universal vision to positively impact the communities and cultures we partner with."

A veteran of the capital markets, cannabis and hemp industries, Holzworth has specialized experience in mergers and acquisitions, big data, compliance and regulatory affairs as well as brand development. As Vice President of Business Development for Silo Wellness, he will introduce and scale the Marley-branded mushroom line to the world by establishing relationships with large-scale distributors in the nutraceutical, nutrition, smoke shop and big-box retail markets.

"It is my great pleasure to be entrusted with the awesome responsibility of taking one of the most beloved brand names in the world and applying my experience from the cannabis industry to scale this business exponentially in the immediate future," exclaimed Holzworth. "I look very much forward to assisting Silo Wellness to lead and expand market accessibility, domestically and abroad, to the functional and psychedelics mushroom category. Given my international contacts, global market experience and new business development acumen, I am here to fast-track Silo's industry leadership position and to scale the Marley brand globally in short order."

Silo Wellness is also pleased to announce the appointment of Kenny Choi to the role of Corporate Secretary, effective immediately. The appointment of Mr. Choi follows the resignation of Mo Yang as the Corporate Secretary of Silo Wellness.

About Silo Wellness

The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion. Silo Wellness intends to introduce new, safe and affordable alternatives to current medicines by facilitating entry into new and emerging markets where psychedelics are legal by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing functional mushrooms.

Since its inception, Silo Wellness' activities have focused on: (1) development of psilocybin-free functional mushroom tinctures; (2) the development of the formulation of a psilocybin nasal spray in Jamaica; and (3) offering of Jamaican and Oregon psychedelic wellness retreats as well as the cultivation of psychedelic mushrooms in Jamaica. None of Silo Wellness' products claim to cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities.

For further information, please contact: www.SiloWellness.com

Media Relations:
Stuart Kirby, VP of Marketing & Communications
press@silowellness.com

Silo Wellness Investor Relations:
(604) 343-2724
IR@silowellness.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. Other than statements of historical fact, all statements are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the appointment of officers of Silo Wellness and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • Screening closed for all sites and final participants being scheduled for dosing
  • On track for top-line 6-week primary endpoint results in late Q2

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • 52-week observational follow-up study from Phase 2b reveals single 25 mg COMP360 psilocybin dose offers longer-term antidepressant effects compared to lower doses, with average efficacy for a single dose of 25mg lasting about 12 weeks and substantially longer in a subgroup
  • Findings published in the March edition of the Journal of Clinical Psychiatry

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass Pathways to Participate in Stifel Virtual CNS Forum

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel Virtual CNS Forum at 11:30 am ET on March 18 th , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the TD Cowen 45 th Annual Health Care Conference at 1:10 pm ET on March 3 rd , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×